Plain-English translation of NCT05981274 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking at how recombinant Factor VIII Fc (rFVIIIFc)—a medication that helps your blood clot—affects your bone and joint health if you have severe hemophilia A. Researchers want to understand whether the medication is protecting your bones and joints, and they're trying to find simple blood tests that could help doctors monitor your bone and joint health without expensive imaging scans.
People with hemophilia A often develop joint and bone problems over time, but checking these problems requires expensive scans that can only be done once a year. This study aims to find easier blood tests that could help doctors track bone and joint health more frequently and conveniently.
You likely qualify if…
You likely don't qualify if…
You will have imaging scans of your joints and bones, give blood samples to measure special markers of bone and joint health, and complete quality-of-life questionnaires. These exams will happen before you enroll and then be repeated after you've been on the medication for a period of time. The study collects information both prospectively (going forward) and from your past medical records to build a complete picture of how the treatment affects your bone and joint health.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Taiwan
Sponsor
Tri-Service General Hospital (TSGH)
Enrollment target
~45 participants
Started
July 2023
Primary completion
December 2027
Sex
Male only
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yeu-Chin Chen
Tri-Service General Hospital (TSGH)
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.